The present study is aimed to investigate the treatment benefits of a combination of dietary supplements quercetin, curcumin and vitamin D3 as add-on therapy to the routine care for early mild symptoms of COVID-19 infection in outpatients setting.
There is currently no specific early-stage therapeutic treatment available for COVID-19. Dietary supplements curcumin, quercetin and vitamin D3 have shown strong antioxidant, anti-inflammatory/immunomodulatory and broad-spectrum antiviral effects. The present study is focused to test the combination of oral curcumin, quercetin and vitamin D3 supplements as complementary therapy for outpatients with mild to moderate symptoms of COVID-19 infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
50
A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
This arm will receive standard of care as per the hospital guidelines
Liaquat University Hospital
Jāmshoro, Sindh, Pakistan
SARS-CoV-2 Negativity by RT-PCR
Number of patients testing negative for COVID-19
Time frame: up to 14 days
COVID-19 symptoms improvement
Number of patients with improvement in COVID-19 acute symptoms
Time frame: up to 7 days
Improvement in the serum inflammatory marker level
Changes in the serum CRP level
Time frame: up to 7 days
Improvement in the serum inflammatory marker level
Changes in the serum D-dimer level
Time frame: up to 7 days
Improvement in the serum inflammatory marker level
Changes in the serum LDH level
Time frame: up to 7 days
Improvement in the serum inflammatory marker level
Changes in the serum ferritin level
Time frame: up to 7 days
Hospitalization rate
Number of patients required hospitalization
Time frame: up to 14 days
Length of hospitalization
Number of hospital admission days
Time frame: up to 14 days
Length of supplementary oxygen therapy
Patients requirement oxygen at during hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: up to 14 days
ICU transfer
Numbers of patients progressing to ICU
Time frame: up to 14 days
Mechanical ventilation
Numbers of patients requiring mechanical ventilation at hospital
Time frame: up to 14 days
All cause mortality
Numbers of hospital mortality
Time frame: up to 14 days
Safety and tolerability
Any adverse event due to the investigational treatment
Time frame: up to 14 days